[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100384830":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":32,"centralContacts":49,"locations":55,"responsibleParty":66,"collaborators":10,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":70,"sex":76,"minAge":77,"maxAge":10,"enrollmentInfo":78,"targetDuration":81,"studyType":82,"phases":10,"briefSummary":83,"conditions":84,"keywords":89,"overallStatus":58,"whyStopped":10,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"iOMEDICO AG","INDUSTRY",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"ESCC",null,"250 patients with esophageal squamous cell carcinoma",[13],"Other: Routine care as per site standard",{"label":15,"type":10,"description":16,"interventionNames":17},"GAC","920 patients with gastric adenocarcinoma",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"GEJAC","580 patients with gastroesophageal junction adenocarcinoma",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"EAC","150 patients with esophageal adenocarcinoma",[13],[27],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":10},"OTHER","Routine care as per site standard","Physician's choice according to patient's needs. Routine care as per site standard.",[23,9,15,19],[33,37,40,43,46],{"name":34,"affiliation":35,"role":36},"Tobias Dechow, Prof.","Ravensburg","STUDY_CHAIR",{"name":38,"affiliation":39,"role":36},"Florian Lordick, Prof.","Leipzig",{"name":41,"affiliation":42,"role":36},"Sylvie Lorenzen, Prof.","München",{"name":44,"affiliation":45,"role":36},"Karin Potthoff, Dr.","Freiburg",{"name":47,"affiliation":48,"role":36},"Anke Reinacher-Schick, Prof.","Bochum",[50],{"name":51,"role":52,"phone":53,"phoneExt":10,"email":54},"Adrian Binninger","CONTACT","+49 761 152 42 - 0","info@iomedico.com",[56],{"facility":57,"status":58,"city":59,"state":10,"zip":10,"country":60,"countryCode":61,"cosmosGeoPoint":10,"geoPoint":10,"contacts":62},"Multiple sites, Gemany","RECRUITING","Multiple Locations","Germany","DE",[63],{"name":64,"role":52,"phone":65,"phoneExt":10,"email":54},"iOMEDICO","+49761152420",{"type":67,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100384830","registry-platform-gastricesophageal-cancer-saphir-100384830",false,"NCT04290806","Registry Platform Gastric\u002FEsophageal Cancer (SAPHIR)","Clinical Research Platform For Molecular Testing, Treatment, Quality Of Life And Outcome Of Patients With Esophageal, Gastric Or Gastroesophageal Junction Cancer Requiring Palliative Systemic Therapy","SAPHIR","Inclusion Criteria:\n\n* Histologically proven stage IV (metastatic) ESCC, EAC, GAC or GEJAC\n* Planned palliative systemic first-line therapy\n* Age \\>= 18 years\n* Signed informed consent (IC)\n\n  * Patients answering questionnaires: IC before first therapy cycle\n  * Patients not answering questionnaires: IC latest 4 weeks after start of first therapy cycle\n\nExclusion Criteria:\n\n* No systemic therapy for ESCC, EAC, GAC or GEJAC","ALL","18 Years",{"count":79,"type":80},1900,"ESTIMATED","2 Years","OBSERVATIONAL","The registry aims to collect and analyse information on the antineoplastic treatment of patients with metastatic esophageal, gastric or gastroesophageal junction cancer, treated in palliative intention in daily routine practice in Germany.",[85,86,87,88],"Esophageal Squamous Cell Carcinoma","Gastric Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma","Esophageal Adenocarcinoma",[90,91,92,93,60,94,95],"neoplasms","registry","health services research","epidemiology","palliative treatment","palliative care","2026-01-26",{"date":98,"type":99},"2026-01-28","ACTUAL",{"date":101,"type":99},"2019-12-04",{"date":103,"type":80},"2028-12-31",{"name":5,"class":6},1]